Our Assets.


Since 2018, NETRI has capitalized on its growing expertise to build a strong base of continuously expanding technical and production capabilities, as well as an international commercial footprint.

Know-how assets
Production assets
Commercial assets

Know-how Assets.

NETRI has developed recognized know-how in microfluidics neuro-engineering, cell culture of human induced pluripotent stem cells, and digital tools development. Since the beginning, we have nurtured our skillsets in multiple microfluidics, cells and readouts protocols: immunofluorescence, dedicated biomarkers, LC/MS, and ELISA assays in microfluidics devices.

Open innovation developement with our clients
9 cell seeding and culture/co-culture protocols
42 immunostaining protocols
Electrophysiological recording using MicroElectrodes Arrays
Scientific valorisation through peer-reviewed publications, poster, international conferences

Production Assets.

NETRI manufactures devices and models using its pilot production units of microfluidic devices and cell culture automated labs. With more than 200 m² of production platform, 3 devices are marketed and divided into 3 options. Five types of neurons human cells derived from stem cells as well as primary keratinocytes and endothelial cells are marketable with our devices. In 2024, with the construction of its production site, NETRI will increase the production capacity of its pre-industrial pilot units with:

100 m² of ISO 8 laboratory for its ready-to-use devices production unit
100 m² of P2 laboratory for its pre-industrial unit of pre-cultivated devices
2 secure computing bays, for its artificial intelligence data analysis production unit
A dedicated area for its biobank

Commercial Assets.

NETRI holds 9 proprietary patents and undisclosed manufacturing skillsets. Our devices are compatible with all cell types and we have established contracted partnerships with key cell suppliers, technological enablers, and high-content screening imaging and lab automation providers. NETRI has established strategic partnerships to create commercial alliances, growth relays and provide innovative combined solutions to the healthcare ecosystem.

Axion BioSytems, technology supplier
Axol Biosciences, human iPSC-derived cells supplier
ETAP-Lab, a CRO specialized in in vivo NDD


Discover our new exclusive package
organs-on-chip kits and all our
neuro-organs-on-chip devices.



Quickly and easily adopt organs-on-chip

into users’ research